Home / Market News / $MRNA
fiscal.ai Corporate Catalyst Impact 55/100 ● positive

Goldman Sachs Adjusts Price Target on Moderna

Nov 9, 2026, 11:35 AM UTC · Primary ticker $MRNA

Goldman Sachs has updated its valuation of Moderna, increasing its price target on the company's stock from $137 to $195. This adjustment reflects Goldman's revised assessment of Moderna's market position and financial outlook, indicating a more optimistic view from the investment bank.

Goldman Sachs has raised its price target for Moderna (MRNA) from $137 to $195. This upward revision signals a more favorable outlook from a prominent investment bank regarding Moderna's future performance and market standing. While not a direct corporate action by Moderna, an increased price target from a firm like Goldman Sachs can influence investor sentiment and potentially lead to short-term positive price movement for MRNA. For traders, this presents an opportunity to capitalize on potential upward momentum, though the long-term implications depend on Moderna's actual financial performance and pipeline developments. The key risk is that the market may have already priced in such analyst upgrades, or that other factors could outweigh this positive sentiment.

$MRNA positive Price target increase by major investment bank
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.